Research Trends in the Efficacy of Stem Cell Therapy for Hepatic Diseases Based on MicroRNA Profiling
Minyeoung Kweon1, Jae Yeon Kim2, Ji Hye Jun2
1Department of Molecular and Cellular Biology, University of Glasgow, Glasgow G12 8QQ, UK.
Abstract:
Liver diseases, despite the organ's high regenerative capacity, are caused by several environmental factors and persistent injuries. Their optimal treatment is a liver transplantation. However, this option is limited by donor shortages and immune response issues. Therefore, many researchers have been interested in identifying the therapeutic potential in treating irreversible liver damage based on stem cells and developing suitable therapeutic agents. Mesenchymal stem cells (MSCs), which are representative multipotent stem cells, are known to be highly potential stem cell therapy compared to other stem cells in the clinical trial worldwide. MSCs have therapeutic potentials for several hepatic diseases such as anti-fibrosis, proliferation of hepatocytes injured, anti-inflammation, autophagic mechanism, and inactivation of hepatic stellate cells. There are much data regarding clinical treatments, however, the data for examining the efficacy of stem cell treatment and the correlation between the stem cell engraftment and the efficacy in liver diseases is limited due to the lack of monitoring system for treatment effectiveness. Therefore, this paper introduces the characteristics of microRNAs (miRNAs) and liver disease-specific miRNA profiles, and the possibility of a biomarker that miRNA can monitor stem cell treatment efficacy by comparing miRNAs changed in liver diseases following stem cell treatment. Additionally, we also discuss the miRNA profiling in liver diseases when treated with stem cell therapy and suggest the candidate miRNAs that can be used as a biomarker that can monitor treatment efficacy in liver diseases based on MSCs therapy.
Insights
Mesenchymal stem cells (MSCs) show promise for treating liver diseases. MicroRNAs (miRNAs) may serve as biomarkers to monitor the effectiveness of MSC therapy for liver conditions.
Area of Science:
- Hepatology
- Regenerative Medicine
- Biomarker Discovery
Background:
- Liver diseases pose significant health challenges, with transplantation facing limitations like donor shortages.
- Mesenchymal stem cells (MSCs) are a promising therapeutic avenue for liver diseases due to their regenerative and immunomodulatory properties.
- Current monitoring of stem cell therapy efficacy in liver diseases is limited, hindering treatment optimization.
Purpose of the Study:
- To explore the potential of microRNAs (miRNAs) as biomarkers for monitoring stem cell therapy in liver diseases.
- To investigate miRNA profiles in liver diseases following stem cell treatment.
- To identify candidate miRNAs for assessing the efficacy of Mesenchymal stem cell (MSC) therapy.
Main Methods:
- Review of existing literature on stem cell therapy for liver diseases.
- Analysis of microRNA (miRNA) characteristics and liver disease-specific miRNA profiles.
- Comparison of miRNA changes in liver diseases after stem cell treatment.
Main Results:
- Mesenchymal stem cells (MSCs) demonstrate therapeutic potential including anti-fibrosis and hepatocyte proliferation.
- MicroRNAs (miRNAs) show altered expression patterns in liver diseases post-stem cell treatment.
- Specific miRNAs are identified as potential indicators of treatment response.
Conclusions:
- MicroRNAs (miRNAs) hold promise as non-invasive biomarkers to monitor the efficacy of Mesenchymal stem cell (MSC) therapy in liver diseases.
- Further research into miRNA profiling can enhance the clinical application of stem cell treatments for hepatic conditions.
- Identifying reliable miRNA biomarkers will improve patient outcomes and treatment strategies for liver diseases.
More Related Videos
Related Concept Videos
01:19Mesenchymal Stem Cells
01:22iPS Cell Differentiation
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...